glp-1 stands for Glucagon-like peptide-1 What Should I Expect the

Many patients successfully transition off therapy if they've simultaneously built lasting dietary and exercise routines

metformin 1000 mg BID led to conflicting results on hyperandrogenism

The agency found no clinical need for it when approved versions exist

Regulatory Context for Compounded Medications: February 2025: FDA declared semaglutide shortage resolved, triggering changes in compounding permissions

GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S

Thats why I believe companies like HIMS and HERS (in the US), Numan (UK) and others may be in a good position to capitalize on this and any other opportunity that emerges (think: peptides, testosterone replacement therapy and more), although regulation remains a massive risk for the time being